PASSAGE BIO INC (PASG)
US7027121000 - Common Stock
ChartMill assigns a Buy % Consensus number of 85% to PASG. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 7.14. This target is 526.32% above the current price.
PASG was analyzed by 11 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about PASG.
In the previous month the buy percentage consensus was at a similar level.
PASG was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-05 | Canaccord Genuity | Reiterate | Buy -> Buy |
| 2023-11-14 | Raymond James | Maintains | Outperform -> Outperform |
| 2023-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-05-12 | Raymond James | Maintains | Outperform -> Outperform |
| 2022-12-15 | Chardan Capital | Maintains | Buy |
| 2022-11-11 | Guggenheim | Maintains | Buy |
| 2022-11-11 | Citigroup | Maintains | Buy |
| 2022-11-08 | Canaccord Genuity | Initiate | Buy |
| 2022-05-17 | Raymond James | Maintains | Outperform |
| 2022-05-17 | Citigroup | Maintains | Buy |
| 2022-03-08 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2022-03-04 | Raymond James | Maintains | Outperform |
| 2022-01-19 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2021-07-01 | Raymond James | Initiate | Outperform |
| 2021-06-15 | BTIG | Initiate | Buy |
| 2021-03-08 | Chardan Capital | Maintains | Buy |
| 2021-03-04 | Goldman Sachs | Upgrade | Neutral -> Buy |